Nuvaxovid (COVID-19 Vaccine (recombinant, adjuvanted))
- Region
- 🇪🇺 EU
- Active substance
- COVID-19 Vaccine (recombinant, adjuvanted)
- Company
- Sanofi Winthrop Industrie
- Status
- Authorised
- Therapeutic area
- COVID-19 virus infection
- CHMP opinion
- Mon 20 Dec 2021
- EU approval
- Mon 20 Dec 2021
- Designations
- Additional monitoring
- Application
- EMEA/H/C/005808
- ATC
- J07BN04
- Official record
- www.ema.europa.eu
Indication
Nuvaxovid is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.The use of this vaccine should be in accordance with official recommendations. Nuvaxovid XBB.1.5 is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older.The use of this vaccine should be in accordance with official recommendations. Nuvaxovid XFG is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 12 years of age and older. The use of this vaccine should be in accordance with official recommendations.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Bimervax Authorised · Hipra Human Health S.L.
- 🇪🇺 VidPrevtyn Beta Withdrawn · Sanofi Pasteur
Follow Nuvaxovid
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.